Research Paper Volume 13, Issue 11 pp 15336—15352

Pharmacological targeting of TNS3 with histone deacetylase inhibitor as a therapeutic strategy in esophageal squamous cell carcinoma


Figure 2. Putative oncogene TNS3 is mitigated by LMK-235. (A) Venn diagrams of the 56 putative tumor suppressors and 55 putative oncogenes. (B) Volcano plot exhibits the DEGs mediated by LMK-235, including the selected 10 genes. (C) Loss-of-function proliferation high-content based siRNA screen of the selected 10 genes. (D) Immunofluorescence of TNS3 in KYSE150 and TE-1, treated with LMK-235. Red: TNS3, Green: α-Tubulin, Blue: DAPI. Scale bar = 20 μm. (E) qRT-PCR analysis of TNS3 expression in Het-1A, TE-1, and KYSE150 cells treated with LMK-235 and Vorinostat. Data are normalized to GAPDH. (F) qRT-PCR analysis of TNS3 expression in EC109, KYSE150, KYSE510, TE-1, and TE-7 cells treated with LMK-235. Data are relative to vehicle control and normalized to GAPDH. (C, E, F). Error bar denotes SEM of three replicates.